These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22233356)

  • 21. Total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in patients with severe persistent allergic asthma: its relation to omalizumab treatment.
    Yalcin AD; Gorczynski RM; Parlak GE; Kargi A; Bisgin A; Sahin E; Kose S; Gumuslu S
    Clin Lab; 2012; 58(1-2):89-96. PubMed ID: 22372350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two cases of delayed granulomatous reactions to the cosmetic filler Dermalive, a hyaluronic acid and acrylic hydrogel.
    Angus JE; Affleck AG; Leach IH; Millard LG
    Br J Dermatol; 2006 Nov; 155(5):1077-8. PubMed ID: 17034549
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy of combination light-emitting diode (635 and 830 nm) therapy in treating local injection-site reactions after filler.
    Yoo KH; Yeo IK; Hyun MY; Hong CK; Kim BJ
    Clin Exp Dermatol; 2015 Apr; 40(3):333-5. PubMed ID: 25266806
    [No Abstract]   [Full Text] [Related]  

  • 25. Persistent elevation of peripheral blood myeloid cell counts associated with omalizumab therapy.
    Banh HL; Trevoy J; Pabst H; Beach J; Vethanayagam D
    Am J Health Syst Pharm; 2012 Feb; 69(4):302-6. PubMed ID: 22302255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Omalizumab: NICE to USE you, to LOSE you NICE.
    Bush A; Pavord ID
    Thorax; 2013 Jan; 68(1):7-8. PubMed ID: 23229814
    [No Abstract]   [Full Text] [Related]  

  • 27. Omalizumab and the risk of malignancy: results from a pooled analysis.
    Busse W; Buhl R; Fernandez Vidaurre C; Blogg M; Zhu J; Eisner MD; Canvin J
    J Allergy Clin Immunol; 2012 Apr; 129(4):983-9.e6. PubMed ID: 22365654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Foreign body reaction triggered by cytotoxic T lymphocyte-associated protein 4 blockade 25 years after dermal filler injection.
    Bisschop C; Bruijn MS; Stenekes MW; Diercks GF; Hospers GA
    Br J Dermatol; 2016 Dec; 175(6):1351-1353. PubMed ID: 27086747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Omalizumab: new drug. Asthma: too many unknowns for an anti-IgE.
    Prescrire Int; 2007 Oct; 16(91):179-82. PubMed ID: 17926440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Foreign body granuloma caused by hyaluronic acid/dextranomer microsphere filler injection.
    Yang JH; Lee SM; Won CH; Chang SE; Lee MW; Choi JH; Moon KC
    Int J Dermatol; 2012 Dec; 51(12):1517-8. PubMed ID: 23171022
    [No Abstract]   [Full Text] [Related]  

  • 32. [Pneumology. Anti-IgE antibodies in the treatment of asthma].
    Leuenberger P; Sauty A; Rochat T
    Rev Med Suisse; 2007 Jan; 3(93):56-9. PubMed ID: 17354662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Localized granulomatous reaction to a semi-permanent hyaluronic acid and acrylic hydrogel cosmetic filler.
    Sidwell RU; Dhillon AP; Butler PE; Rustin MH
    Clin Exp Dermatol; 2004 Nov; 29(6):630-2. PubMed ID: 15550141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant asthma medication use in patients receiving omalizumab: results from three large insurance claims databases.
    Lafeuille MH; Duh MS; Zhang J; Wertz D; Gu T; Swensen A; Lefebvre P
    J Asthma; 2011 Nov; 48(9):923-30. PubMed ID: 21978232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
    Holgate ST; Djukanović R; Casale T; Bousquet J
    Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.
    Shimizu Y; Dobashi K; Fueki N; Fueki M; Okada T; Tomioka S; Makino S; Mori M
    J Biol Regul Homeost Agents; 2011; 25(2):177-86. PubMed ID: 21880206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
    Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M
    J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma.
    Korn S; Schumann C; Kropf C; Stoiber K; Thielen A; Taube C; Buhl R
    Ann Allergy Asthma Immunol; 2010 Oct; 105(4):313-9. PubMed ID: 20934632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-IgE therapy with omalizumab decreases endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthma.
    Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Bodzenta-Lukaszyk A
    Respiration; 2010; 80(6):534-42. PubMed ID: 20588001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistent delayed-type hypersensitivity reaction to injectable non-animal-stabilized hyaluronic acid.
    Arron ST; Neuhaus IM
    J Cosmet Dermatol; 2007 Sep; 6(3):167-71. PubMed ID: 17760694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.